Comparative effects of early postnatal ibuprofen and indomethacin on VEGF, IGF-I, and GH during rat ocular development

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 7, 2006, Pages 3036-3043

  Beharry, Kay D A ^a   Modanlou, Houchang D ^a,d,e   Hasan, Jamal ^a,b   Gharraee, Zahra ^a,b   Abad Santos, Patricia ^b   Sills, Jeremy H ^b   Jan, Amanda ^b   Nageotte, Stephen ^b   Aranda, Jacob V ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MILLER CHILDREN S HOSPITAL   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Building 56   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; IBUPROFEN; INDOMETACIN; MESSENGER RNA; PIGMENT EPITHELIUM DERIVED FACTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; SODIUM CHLORIDE; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EYE DEVELOPMENT; GENETIC TRANSCRIPTION; LOW DRUG DOSE; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE HOMOGENATE; VITREOUS BODY; ANIMAL; COMPARATIVE STUDY; EYE; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PREGNANCY; RETINA; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; CYCLOOXYGENASE INHIBITORS; EYE; FEMALE; GROWTH HORMONE; IBUPROFEN; INDOMETHACIN; INJECTIONS, INTRAPERITONEAL; INSULIN-LIKE GROWTH FACTOR I; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 33746761788     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0057     Document Type: Article

References (57)

1. Friedman Z, Whitman V, Maisels MJ, Berman W Jr, Marks KH, Vesell ES. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol. 1978;18:272-279.
2. Meyers RL, Alpan G, Lin E, Clyman RI. Patent ductus arteriosus, indomethacin, and intestinal distention: effects of intestinal blood flow and oxygen consumption. Pediatr Res. 1991;29:569-574.
3. Gleason CA. Prostaglandins and the developing kidney. Semin Perinatol. 1987;11:12-21.
4. Rudolph AM, Heymann MA. Hemodynamic changes induced by blockers of prostaglandin synthesis in the fetal lamb in utero. Adv Prostaglandins Thromboxane Res. 1978:4:231-237.
5. Norton ME, Merril J, Cooper B, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med. 1993;329:1602-1607.
6. Laudignon N, Chemtob S, Bard H, Aranda JV. Effect of indomethacin on cerebral blood flow velocity of premature newborns. Biol Neonate. 1988;54:254-262.
7. Van Bel F, Van de Bor M, Stijnen T, Baan J, Ruys JH. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect. Pediatrics. 1989;84:802-807.
8. Pryds O, Greisen G, Johansen KH. Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus. Eur J Pediatr. 1988;147:315-316.
9. Mardoum R, Bejar R, Merritt TA, Berry C. Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants. J Pediatr. 1991;118:112-115.
10. Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai. 2003;86(suppl 3):S563-S569.
11. Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA. 1996;275:539-544.
12. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr. 2005;164:135-140.
13. Chemtob S, Laudignon N, Beharry K, et al. Effects of prostaglandins and indomethacin on cerebral blood flow and cerebral oxygen consumption of conscious newborn piglets. Dev Pharmacol Ther. 1990;14:1-14.
14. Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child. 1997;76:F179-F184.
15. Nandgaonkar BN, Rotschild T, Yu K, Higgins RD. Indomethacin improves oxygen-induced retinopathy in the mouse. Pediatr Res. 1999;46:184-188.
16. Sharma J, Barr SM, Geng Y, Yun Y, Higgins RD. Ibuprofen improves oxygen-induced retinopathy in a mouse model. Curr Eye Res. 2003;27:309-314.
17. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin Cancer Res. 2003;9:3150-3157.
18. Castro MR, Lutz D, Edelman JL. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res. 2004;79:275-285.
19. Chemtob S, Beharry K, Rex J, Chatterjee T, Varma DR, Aranda JV. Ibuprofen enhances retinal and choroidal blood flow autoregulation in newborn piglets. Invest Ophthalmol Vis Sci. 1991;32:1799-1807.
20. Darlow BA, Horwood LJ, Clemett RS. Retinopathy of prematurity: risk factors in a prospective population-based study. Paediatr Perinat Epidemiol. 1992;6:62-80.
21. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15-35.
22. 121. J Biol Chem. 2001;276:25520-25531.
23. Ozaki NK, Beharry KD, Nishihara KC, et al. Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia. Invest Ophthalmol Vis Sci. 2002;43:1546-1557.
24. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: Relevance to clinical ROP. Mol Vis. 2004;10:512-520.
25. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028.
26. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
27. Robbins SG, Rajaratnam VS, Penn JS. Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina. Growth Factors. 1998;16:1-9.
28. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
29. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA. 2001;98:5804-5808.
30. Hellstrom A, Engstrom E, Hard A-L, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003;112:1016-1020.
31. Simó R, Lecube A, Segura RM, Arumí JG, Hernández C. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Clin Sci (Lond). 2003;104:223-230.
32. Hellstrom A, Svensson E, Carlsson B, Niklasson A, Albertsson-Wikland K. Reduced retinal vascularization in children with growth hormone deficiency. Clin Endocrinol Metab. 1999;84:795-798.
33. Hikino S, Ihara K, Yamamoto J, et al. Physical growth and retinopathy in preterm infants: involvement of IGF-I and GH. Pediatr Res. 2001;50:732-736.
34. Modanlou HD, Gharraee Z, Hasan J, Waltzman J, Nageotte S, Beharry KD. Ontogeny of vascular endothelial growth factor, insulin-like growth factor-I, and growth hormone in the rat systemic circulation, vitreous fluid, and retinal homogenates from birth to weaning. Invest Ophthalmol Vis Sci. 2006;47:738-744.
35. Pavelock K, Braas K, Ouafik L, Osol G, May V. Differential expression and regulation of the vascular endothelial growth factor receptors of neuropilin-1 and neuropilin-2 in rat uterus. Endocrinology. 2001;142:613-622.
36. Patel J, Roberts I, Assopardi D, Hamilton P, Edwards AD. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res. 2000;47:36-42.
37. Smyth JM, Collier PS, Dawish M, et al. Intravenous indomethacin in preterm infants with symptomatic patent ductus arteriosus: a population pharmacokinetic study. Br J Clin Pharmacol. 2004;58:249-258.
38. Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr. 1997;86:289-293.
39. Sharma PK Garg SK, Narang A. Pharmacokinetics of oral ibuprofen in preterm infants. J Clin Pharmacol. 2003;43:968-973.
40. Ashton N, Blach R. Studies in developing retinal vessels. VIII. Effect of oxygen on the vessels of the ratling. Br J Ophthalmol. 1961;45:321-340.
41. Penn JS, Tolman BL, Lowery LA, Koutz CA. Oxygen-induced retinopathy in the rat: hemorrhages and dysplasias may lead to retinal detachment. Curr Eye Res. 1992;11:939-953.
42. Robinson SR, Dreher B. The visual pathways of eutherian mammals and marsupials develop according to a common timetable. Brain Behav Evol. 1990;36:177-195.
43. Dreher B, Robinson SR. Development of the retinofugal pathway in birds and mammals: evidence for a common "timetable". Brain Behav Evol. 1988;31:369-390.
44. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
45. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of VEGF in ischemic retinas of Maccaca fasicularis. Invest Ophthalmol Vis Sci. 1996;37:1334-1340.
46. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M. Involvement of Flt-1 tyrosinase kinase (vascular endothelial growth factor receptor-1) in pathologic angiogenesis. Cancer Res. 2001;61:1207-1213.
47. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
48. Kirtikara K, Swangkul S, Ballou LR. The analysis of nonsteroidal antiinflammatory drug selectivity in prostaglandin G/H (PGHS)-null cells. Inflamm Res. 2001;50:327-332.
49. Uzan A. The unexpected side effects of new nonsteroidal anti-inflammatory drugs. Expert Opin Emerg Drugs. 2005;10:687-688.
50. Akarasereenont PC, Techatraisak K, Thaworn A, Chotewuttakorn S. The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase. Mediators Inflamm. 2002;11:17-22.
51. Tamura M, Sebastian S, Gurates B, Yang S, Fang Z, Bulun SE. Vascular endothelial growth factor upregulates cyclooxygenase-2 expression in human endothelial cells. J Clin Endocrinol Metab. 2002;87:3504-3507.
52. Baker J. Role of insulin and IGF in embryonic and postnatal growth. Cell. 1993;75:73-82.
53. Le Roith D. Insulin-like growth factors. Semin Med Beth Israel Deaconess Med Center. 1997;336:633-640.
54. Schmitt JK. Indomethacin increases plasma growth hormone levels in man. Am J Med Sci. 1990;300:144-147.
55. Cavagnini F, Di Lando A, Invitti C, et al. Effects of acetylsalicylic acid and indomethacin on growth hormone secretion in man. Metabolism. 1977;26:193-200.
56. Punglia RS, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997;46:1619-1626.
57. Arnold DR, Moshayedi P, Schoen TJ, Jones BE, Chader GJ, Waldbillig RJ. Distribution of IGF-I, IGF binding proteins (IGFBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. Exp Eye Res. 1993;56:555-565.